Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label, Single Arm Study of MK-7119 in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 2 Open-label, Single Arm Study of MK-7119 in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms MK-7119-001
  • Sponsors Pfizer

    • Most Recent Events

    • 30 Nov 2022 Planned primary completion date changed from 6 Jan 2023 to 17 Jul 2023.
    • 30 Nov 2022 Status changed from recruiting to active, no longer recruiting.
    • 31 Mar 2021 Time frame of primary endpoint changed from 22.5 months to 21 months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top